argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025

Core Insights - argenx is hosting a webinar on September 16, 2025, focusing on its MuSK biology research and development strategy [1][2] - The webinar will feature discussions on the ARGX-119 program, which targets neuromuscular diseases such as congenital myasthenic syndromes, amyotrophic lateral sclerosis, and spinal muscular atrophy [2] Company Overview - argenx is a global immunology company dedicated to improving the lives of individuals with severe autoimmune diseases [4] - The company collaborates with leading academic researchers through its Immunology Innovation Program to develop novel antibody-based medicines [4] - argenx has developed the first approved neonatal Fc receptor blocker and is exploring its potential across various serious autoimmune diseases [4]